By Connor Hart
Palantir Technologies blew past Wall Street's expectations for the fourth quarter as demand for its artificial-intelligence products continued to expand. The software company notched revenue of $828 million, up 36% from last year and ahead of the $776 million that analysts polled by FactSet were expecting. The beat was driven by momentum in the company's U.S. business, which grew 52% year-over-year. For 2025, Palantir forecast revenue of $3.741 billion to $3.757 billion, above the $3.503 billion that analysts had modeled. Shares jump 22%, to $102.40, in after-hours trading.
Synaptics Chief Executive Michael Hurlston stepped down from the company's top role to become chief executive and president of Lumentum. Hurlston left the artificial-intelligence company to start as head of Lumentum on Friday, according to Lumentum, which makes products for cloud and AI applications. Synaptics' board launched a search for a new top executive and said Ken Rizvi, its chief financial officer, will step in as interim CEO. Shares fall 5.9%, to $80, in post-market trading.
J&J Snack Foods logged lower revenue and profit in its fiscal first quarter, and cited near-term challenges including higher input costs and foreign-exchange headwinds. The maker of Super Pretzels soft pretzels, Dippin' Dots ice cream and Icee beverages posted adjusted earnings of 33 cents a share on revenue of $362.6 million, compared with analyst expectations for adjusted earnings of 59 cents a share on revenue of $360.9 million. Chief Executive Dan Fachner said the quarter was hurt by near-term challenges, such as a less favorable sales mix and higher input costs that weren't fully covered with price increases. Shares fall 5%, to $126, in after-hours trading.
Serina Therapeutics closed on a $5 million tranche of equity financing. The company said it successfully closed the second tranche on a $10 million equity financing agreement with strategic shareholder JuvVentures (UK). The proceeds will be used to continue advancing its SER-252, or POZ-apomorphine, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of this year. Shares climb 11%, to $5.48, in post-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
February 03, 2025 18:32 ET (23:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.